Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co. s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer medication, vitamins, food preservative, flavoring agent, and sweetening material. Co. is also engaged in the manufacture and sale of pharmaceutical production system and machines.
Quote | Eisai Co Ltd (OTCMKTS:ESALF)
Last: | $42.85 |
---|---|
Change Percent: | 0.56% |
Open: | $42.6 |
Close: | $42.85 |
High: | $42.85 |
Low: | $42.6 |
Volume: | 1,650 |
Last Trade Date Time: | 05/21/2024 03:00:00 am |
News | Eisai Co Ltd (OTCMKTS:ESALF)
2024-05-16 21:14:05 ET Eisai Co Ltd. (ESALF) Q4 2024 Results Conference Call May 16, 2024 2:00 AM ET Company Participants Haruo Naito - CEO, Representative Corporate Officer & Director Keisuke Naito - SVP, Chief Strategy, Planning & Ecosystem Officer and Acti...
2024-05-15 12:52:06 ET More on Eisai Eisai: All About Lenvima And Leqembi Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report Historical earnings dat...
Message Board Posts | Eisai Co Ltd (OTCMKTS:ESALF)
Subject | By | Source | When |
---|---|---|---|
is it bear time? Or do we go bull? | stocktrademan | investorshub | 06/25/2023 9:15:45 PM |
$ESALF recent news/filings | stocktrademan | investorshub | 07/21/2015 5:37:47 PM |
Stock_Tracker: Latest Eisai Co Ltd (ESALF) Headlines Arterial Thrombosis - Pipeline Review, H2 2013 | Stock_Tracker | investorshangout | 03/09/2014 10:43:46 PM |
chartguy89: ESALF 38.75 Stock Charts $ESALF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 7:59:58 AM |
chartguy89: ESALF Stock Charts Last: +1.20 Wednesday, February 26, 2014 at 12:11:28 AM $ESALF | chartguy89 | investorshangout | 02/26/2014 5:11:39 AM |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and...
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures TOKYO, May 13, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house disc...
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...